Market closed
Jazz Pharmaceuticals/$JAZZ
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Jazz Pharmaceuticals
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
Ticker
$JAZZ
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Dublin, Ireland
Employees
2,800
Website
JAZZ Metrics
BasicAdvanced
$7.2B
Market cap
16.95
P/E ratio
$7.04
EPS
0.57
Beta
-
Dividend rate
Price and volume
Market cap
$7.2B
Beta
0.57
52-week high
$134.17
52-week low
$99.06
Average daily volume
635K
Financial strength
Current ratio
4.263
Quick ratio
3.245
Long term debt to equity
147.49
Total debt to equity
148.233
Interest coverage (TTM)
2.69%
Management effectiveness
Return on assets (TTM)
4.62%
Return on equity (TTM)
12.09%
Valuation
Price to earnings (TTM)
16.946
Price to revenue (TTM)
1.862
Price to book
1.76
Price to tangible book (TTM)
-2.64
Price to free cash flow (TTM)
6.628
Growth
Revenue change (TTM)
5.23%
Earnings per share change (TTM)
458.10%
3-year revenue growth (CAGR)
11.72%
3-year earnings per share growth (CAGR)
36.58%
What the Analysts think about JAZZ
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Jazz Pharmaceuticals stock.
JAZZ Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
JAZZ Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
JAZZ News
AllArticlesVideos
Jazz Pharmaceuticals receives FDA approval for biliary tract cancer treatment
Reuters·23 hours ago
Jazz Pharmaceuticals: Unexpected Wins Improve The Long-Term Outlook
Seeking Alpha·1 month ago
Jazz Pharmaceuticals' Zepzelca/Tecentriq Combo Regimen Can Potentially Delay Disease Progression, Extend Survival In Aggressive Form Of Lung Cancer
Benzinga·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Jazz Pharmaceuticals stock?
Jazz Pharmaceuticals (JAZZ) has a market cap of $7.2B as of November 22, 2024.
What is the P/E ratio for Jazz Pharmaceuticals stock?
The price to earnings (P/E) ratio for Jazz Pharmaceuticals (JAZZ) stock is 16.95 as of November 22, 2024.
Does Jazz Pharmaceuticals stock pay dividends?
No, Jazz Pharmaceuticals (JAZZ) stock does not pay dividends to its shareholders as of November 22, 2024.
When is the next Jazz Pharmaceuticals dividend payment date?
Jazz Pharmaceuticals (JAZZ) stock does not pay dividends to its shareholders.
What is the beta indicator for Jazz Pharmaceuticals?
Jazz Pharmaceuticals (JAZZ) has a beta rating of 0.57. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.